FMP
Insmed Incorporated Review Following Q3 Results
Nov 2, 2021 2:42 AM - Davit Kirakosyan(Last modified: Dec 19, 2023 6:49 PM)
Image credit: FMP
Insmed Incorporated (NASDAQ:INSM) reported its Q3 results last week, with disappointing revenues providing more evidence of the continuous slowdown due to the delta variant. ARIKAYCE Q3 revenue, primarily impacted by the regional variability of the delta variant, was 4% and 9% shy of consensus estimates. R&D spending was higher due to the ongoing clinical studies.
Analysts at Berenberg Bank believe that the performance has been overall positive despite pandemic-related headwinds. The analysts remain positive on the long-term growth prospects for Insmed, anticipating a recovery in Q4 and beyond.
Other Blogs
Sep 10, 2024 11:33 AM - Parth Sanghvi
Best Alternatives to Yahoo Finance for Downloading Historical Stock Data
When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...
Nov 8, 2024 10:30 AM - Sanzhi Kobzhan
Understanding Equity Valuation: When to Use DCF, DDM, and Price-Income (Multiplicators) Models
When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...
Nov 22, 2024 10:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
